H.C. Wainwright maintains $19 target on Arcutis stock

H.C. Wainwright reaffirmed its Buy rating and $19 price target for Arcutis Biotherapeutics (ARQT) following positive open-label extension study data for Zoryve cream in treating atopic dermatitis, emphasizing its durability and tolerability in both adults and children. The firm also anticipates FDA approval for Zoryve cream 0.05% by October 13. Arcutis recently received FDA approval for ZORYVE foam 0.3% for plaque psoriasis, and Jefferies raised its price target to $20 after strong first-quarter ZORYVE revenues of $63.8 million, representing a 196% year-over-year increase.

Analysis

Arcutis Biotherapeutics (NASDAQ: ARQT) has received a reaffirmed Buy rating and a $19.00 price target from H.C. Wainwright, with the stock currently trading at $14.37, highlighting the positive open-label extension study data for Zoryve cream in atopic dermatitis (AD). This data underscores the product's durability and favorable tolerability, particularly for long-term use in patients including young children, supporting its potential market expansion. Analyst consensus price targets range from $19 to $29, indicating significant perceived upside. The company's operational strength is underscored by an impressive gross profit margin of 88%. Confidence is high for the upcoming Prescription Drug User Fee Act (PDUFA) decision for Zoryve cream 0.05% on October 13, buoyed by Arcutis' successful track record in label expansions. Further positive developments include the recent FDA approval of ZORYVE foam 0.3% for plaque psoriasis in adults and children aged 12 and older. Financially, Arcutis reported strong first-quarter ZORYVE product revenues of $63.8 million, a 196% year-over-year increase, despite a slight 2% sequential decrease attributed to typical insurance changes. This revenue performance prompted Jefferies to increase its price target to $20. The company's adjusted earnings per share for Q1 was -$0.20, slightly exceeding analyst projections, and ZORYVE has seen over 425,000 prescriptions filled since launch, indicating robust demand. Future growth catalysts include a PDUFA action date in May 2025 for ZORYVE foam 0.3% for plaque psoriasis.

Key Decisions for Investors

• Investors should consider the significant upside potential indicated by analyst price targets ($19-$29) relative to the current trading price, supported by strong product data and revenue growth for Zoryve.
• The upcoming PDUFA decision on October 13 for Zoryve cream 0.05% represents a key near-term catalyst; a positive outcome could further de-risk the stock and validate the company's label expansion strategy.
• Monitor ongoing ZORYVE sales momentum, particularly its ability to penetrate the atopic dermatitis and plaque psoriasis markets further, and progress towards the May 2025 PDUFA date for ZORYVE foam.